Trial Profile

Towards Eradication: Reducing Proviral HIV DNA With Interferon-a Immunotherapy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2b (Primary)
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms BEAT-HIV

Most Recent Events

11 Mar 2020 Results (n=13) evaluating baseline inducible HIV p 24 informs viral control during interferon monotherapy, presented at the 27th Conference on Retroviruses and Opportunistic Infections
07 Mar 2019 Results assessing the effect of pIFN alpha on latent HIV by measuring inducible HIV expression from CD4 cells isolated from chronically infected, ART-suppressed individuals receiving pIFN alpha-2b immunotherapy in this trial, were presented at the 26th Conference on Retroviruses and Opportunistic Infections.
03 Apr 2018 Planned End Date changed from 1 Aug 2018 to 24 Jul 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com